Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis.

Abstract

BackgroundEpidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) are remarkably effective for treating EGFR‐mutant non‐small cell lung cancer (NSCLC). However, the individual role of EGFR‐TKIs in patients with brain metastasis (BM) arising from EGFR‐mutant NSCLC remains unclear.MethodsPatients with BM secondary to NSCLC and harboring EGFR‐activating mutations were retrospectively screened. Patients who received gefitinib or erlotinib to control both extracranial lesions (ECLs) and intracranial lesions (ICLs) were eligible. If ECLs remained stable or remissive while ICLs progressed; asymptomatic BM progressed to symptomatic BM; BM symptoms were not alleviated within two weeks; or BM symptoms deteriorated after initial release, patients received brain radiotherapy or other local treatments and continued taking TKIs until ECLs progression occurred.ResultsIn 43 eligible patients, the objective response and disease control rates for ICLs were 57% and 91%, respectively. Median progression‐free survival (PFS) was 9.3 months. The median PFS for ICLs and ECLs was 9.7 and 13.7 months, respectively. Non‐smokers and second‐line TKIs were found to be independent positive prognostic factors for PFS and overall survival (OS) respectively, with a hazard ratio of 0.29 (95% confidence interval [CI] 0.14–0.61; P = 0.001) and 0.34 (95% CI 0.16–0.70; P = 0.003). No significant difference in median OS was observed between patients who did or did not receive brain radiotherapy (23.6 vs. 18.7 months; P = 0.317).Conclusion EGFR‐TKIs alone are effective for treating BM arising from EGFR‐mutant NSCLC. The efficacy of TKIs in ICLs and ECLs should be evaluated separately.